Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
What happened
FDA inspected the compounding pharmacy in Kennett Square, PA from May 12 to June 9, 2025 and found smoke studies that did not show unidirectional airflow in the sterile work area, plus production surfaces that were porous, particle-generating, hard to clean or visibly dirty. FDA also found the firm had released a tirzepatide injection lot that failed sterility testing and sold subpotent Fluorescein 2% ophthalmic solution, semaglutide injection and tirzepatide injection; between July 2024 and May 2025 it distributed 9 lots with sterility failures and about 25 lots with potency failures. FDA added that 23 out-of-specification investigations from November 2024 to May 2025 did not follow the firm's own procedure, and none documented contacting the patient.
What FDA found
Sterile drugs were made in conditions that may not protect them from contamination, because smoke studies did not show unidirectional airflow in the ISO 5 area.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Production areas had porous, particle-shedding, hard-to-clean or visibly dirty equipment and surfaces.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Fluorescein 2% Ophthalmic Solution was sold at 76% to 86% of its labeled strength.
FDCA section 501(b) [21 U.S.C. § 351(b)]Semaglutide 2.5 mg/mL Injection and Tirzepatide 10 mg/mL Injection were sold at strengths below their labeled amounts.
FDCA section 501(c) [21 U.S.C. § 351(c)]A tirzepatide injection lot that failed sterility testing was released and distributed, and the firm's own procedures allow ophthalmic sterile products to be released 'at risk' before sterility results are back.
FDCA section 501(c) [21 U.S.C. § 351(c)]Labels were false or misleading because the products' actual strength was below the labeled strength.
FDCA section 502(a) [21 U.S.C. § 352(a)]
What FDA wants
FDA tells the firm to reply in writing within 15 working days with the specific steps taken to fix each violation, how recurrence will be prevented, and supporting documents. It strongly recommends a comprehensive assessment of operations, especially aseptic processing, with help from a third-party consultant who has sterile drug manufacturing expertise.
Who should pay attention
- prescribers and patients who received compounded sterile drugs from this pharmacy
- other compounding pharmacies that make sterile products
- clinics and telehealth companies that buy compounded GLP-1 or ophthalmic preparations from outside compounders
This is a summary. Read the original letter on fda.gov.